{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:11:08Z","timestamp":1788297068928,"version":"build-2803163510"},"reference-count":244,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.addr.2021.113829","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:27:16Z","timestamp":1624519636000},"page":"113829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Nanomedicine at the crossroads \u2013 A quick guide for IVIVC"],"prefix":"10.1016","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9305-7967","authenticated-orcid":false,"given":"Marc-Phillip","family":"Mast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshvardhan","family":"Modh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Champanhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-6082","authenticated-orcid":false,"given":"Jiong-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-3370","authenticated-orcid":false,"given":"Johannes","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Mail\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-0626","authenticated-orcid":false,"given":"Giorgia","family":"Pastorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2789-6463","authenticated-orcid":false,"given":"Matthias G.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.113829_b0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nnano.2017.67","article-title":"The evolving landscape of drug products containing nanomaterials in the United States","volume":"12","author":"D'Mello","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2021.113829_b0010","unstructured":"Global Liposome Drug Delivery (Liposomes Drug Delivery) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023 (WGR3423000), 2018, www.wiseguyreports.com."},{"key":"10.1016\/j.addr.2021.113829_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2019.06.003","article-title":"Nanomedicines - Tiny particles and big challenges","volume":"151\u2013152","author":"Marques","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2013.08.079","article-title":"Nanocarriers for intravenous injection\u2013the long hard road to the market","volume":"457","author":"Wacker","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/nyas.13347","article-title":"Equivalence of complex drug products: advances in and challenges for current regulatory frameworks","volume":"1407","author":"Hussaarts","year":"2017","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1749-6632.2012.06811.x","article-title":"Scientific considerations for complex drugs in light of established and emerging regulatory guidance","volume":"1276","author":"Holloway","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0035","unstructured":"US-FDA, Draft Guidance for Industry: Drug Products, Including Biological Products, that Contain Nanomaterials, 2017."},{"key":"10.1016\/j.addr.2021.113829_b0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2017.07.030","article-title":"The drug delivery field at the inflection point: Time to fight its way out of the egg","volume":"267","author":"Park","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2019.05.044","article-title":"The beginning of the end of the nanomedicine hype","volume":"305","author":"Park","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/21541248.2016.1215283","article-title":"Biology and biogenesis of shed microvesicles","volume":"8","author":"Tricarico","year":"2017","journal-title":"Small GTPases"},{"key":"10.1016\/j.addr.2021.113829_b0055","first-page":"301","article-title":"Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake","volume":"36","author":"Abels","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2021.113829_b0060","series-title":"Bio-Carrier Vectors: Methods and Protocols","first-page":"147","article-title":"Cell-Derived Nanovesicles as Exosome-Mimetics for Drug Delivery: Uses and Recommendations","author":"Ou","year":"2021"},{"key":"10.1016\/j.addr.2021.113829_b0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2021.113829_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fsufs.2019.00023","article-title":"Naturally Occurring Exosome Vesicles as Potential Delivery Vehicle for Bioactive Compounds","volume":"3","author":"Akuma","year":"2019","journal-title":"Front. Sustain. Food Syst."},{"key":"10.1016\/j.addr.2021.113829_b0075","doi-asserted-by":"crossref","first-page":"30087","DOI":"10.3402\/jev.v4.30087","article-title":"Applying extracellular vesicles based therapeutics in clinical trials \u2013 an ISEV position paper","volume":"4","author":"Lener","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcancer.2014.04.007","article-title":"Exosome and microvesicle mediated phene transfer in mammalian cells","volume":"28","author":"Christianson","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.addr.2021.113829_b0085","first-page":"1525","article-title":"Exosome mimetics: a novel class of drug delivery systems","volume":"7","author":"Kooijmans","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2021.113829_b0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/nnm.13.206","article-title":"Could bioengineered exosome-mimetic nanovesicles be an efficient strategy for the delivery of chemotherapeutics?","volume":"9","author":"Jang","year":"2014","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.addr.2021.113829_b0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcyt.2021.01.001","article-title":"Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles","volume":"23","author":"Gimona","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2021.113829_b0100","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/sctm.17-0055","article-title":"Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles","volume":"6","author":"Reiner","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.addr.2021.113829_b0105","doi-asserted-by":"crossref","first-page":"1609206","DOI":"10.1080\/20013078.2019.1609206","article-title":"Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications","volume":"8","author":"Witwer","year":"2019","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0110","unstructured":"US-FDA, Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations, 1997."},{"key":"10.1016\/j.addr.2021.113829_b0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2021.113829_b0120","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/bioinformatics\/btu741","article-title":"EVpedia: a community web portal for extracellular vesicles research","volume":"31","author":"Kim","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.addr.2021.113829_b0125","doi-asserted-by":"crossref","first-page":"e1001450","DOI":"10.1371\/journal.pbio.1001450","article-title":"Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation","volume":"10","author":"Kalra","year":"2012","journal-title":"PLoS Biol."},{"key":"10.1016\/j.addr.2021.113829_b0130","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.3402\/jev.v1i0.18374","article-title":"ExoCarta as a resource for exosomal research","volume":"1","author":"Simpson","year":"2012","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-cellbio-101512-122326","article-title":"Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles","volume":"30","author":"Colombo","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2021.113829_b0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biology9010021","article-title":"Apoptotic Bodies: Particular Extracellular Vesicles Involved in Intercellular Communication","volume":"9","author":"Battistelli","year":"2020","journal-title":"Biology"},{"key":"10.1016\/j.addr.2021.113829_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-013-1084-8","article-title":"Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies","volume":"113","author":"Akers","year":"2013","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0150","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb2502","article-title":"Syndecan\u2013syntenin\u2013ALIX regulates the biogenesis of exosomes","volume":"14","author":"Baietti","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2021.113829_b0155","first-page":"5553","article-title":"Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles","volume":"126","author":"Colombo","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2021.113829_b0160","doi-asserted-by":"crossref","first-page":"1800222","DOI":"10.1080\/20013078.2020.1800222","article-title":"Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging","volume":"9","author":"Gupta","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0165","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri855","article-title":"Exosomes: composition, biogenesis and function","volume":"2","author":"Th\u00e9ry","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.113829_b0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","article-title":"Extracellular vesicles for drug delivery","volume":"106","author":"Vader","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0175","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41556-018-0040-4","article-title":"Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2021.113829_b0180","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1042\/BST20180523","article-title":"Probing the mechanisms of extracellular vesicle biogenesis and function in cancer","volume":"46","author":"Latifkar","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.addr.2021.113829_b0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1194\/jlr.R084343","article-title":"Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology","volume":"60","author":"Skotland","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2021.113829_b0190","doi-asserted-by":"crossref","first-page":"1441017","DOI":"10.1142\/S1793984414410177","article-title":"Exosomes Biogenesis and Potentials in Disease Diagnosis and Drug Delivery","volume":"04","author":"Gu","year":"2014","journal-title":"Nano Life"},{"key":"10.1016\/j.addr.2021.113829_b0195","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/epr.09.17","article-title":"Exosomes: proteomic insights and diagnostic potential","volume":"6","author":"Simpson","year":"2009","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.addr.2021.113829_b0200","first-page":"1184","article-title":"Potential role of exosomes in the pathophysiology, diagnosis, and treatment of hypoxic diseases","volume":"11","author":"Duan","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.addr.2021.113829_b0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ceb.2014.05.004","article-title":"Biogenesis and secretion of exosomes","volume":"29","author":"Kowal","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.addr.2021.113829_b0210","first-page":"1","article-title":"Dancing with Trojan horses: an interplay between the extracellular vesicles and viruses","author":"Badierah","year":"2020","journal-title":"J. Biomol. Struc. Dyn."},{"key":"10.1016\/j.addr.2021.113829_b0215","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.113829_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133272","article-title":"Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers","volume":"20","author":"Chong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0225","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cca.2019.10.022","article-title":"Exosomes: Current use and future applications","volume":"500","author":"Chung","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.addr.2021.113829_b0230","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/10717544.2020.1748758","article-title":"Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source","volume":"27","author":"Meng","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2021.113829_b0235","unstructured":"US-FDA, Guidance for Industry: Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation, 2018"},{"key":"10.1016\/j.addr.2021.113829_b0240","doi-asserted-by":"crossref","first-page":"32945","DOI":"10.3402\/jev.v5.32945","article-title":"Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey","volume":"5","author":"Gardiner","year":"2016","journal-title":"J. Extracell. Vesicles"},{"issue":"2018","key":"10.1016\/j.addr.2021.113829_b0245","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Th\u00e9ry","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0250","doi-asserted-by":"crossref","first-page":"20360","DOI":"10.3402\/jev.v2i0.20360","article-title":"Standardization of sample collection, isolation and analysis methods in extracellular vesicle research","volume":"2","author":"Witwer","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0255","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00000421-199412000-00009","article-title":"A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon","volume":"17","author":"Eckardt","year":"1994","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0260","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0265","article-title":"Characterization and in vitro\/in vivo dissolution of nab-paclitaxel nanoparticles","volume":"68","author":"Desai","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0270","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2020.06.004","article-title":"A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release","volume":"153","author":"Nagpal","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b0275","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2012.46.2309","article-title":"High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","volume":"31","author":"O'Brien","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0280","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Jeffrey","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0285","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0290","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2021.113829_b0295","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.addr.2021.113829_b0300","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.addr.2021.113829_b0305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0310","series-title":"Long Circulating Liposomes: Old Drugs, New Therapeutics","first-page":"29","article-title":"Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations","author":"Boman","year":"1998"},{"key":"10.1016\/j.addr.2021.113829_b0315","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbamem.2006.01.009","article-title":"Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations","volume":"1758","author":"Johnston","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2021.113829_b0320","series-title":"Liposomes","first-page":"40","article-title":"Preparation, Characterization, and Biological Analysis of Liposomal Formulations of Vincristine","author":"Waterhouse","year":"2005"},{"key":"10.1016\/j.addr.2021.113829_b0325","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/bjc.1995.430","article-title":"Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models","volume":"72","author":"Webb","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2021.113829_b0330","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2019.06.029","article-title":"Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans","volume":"308","author":"Jablonka","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpb.2020.02.001","article-title":"Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model","volume":"149","author":"Jablonka","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2020.10.040","article-title":"Correlation between in vitro stability and pharmacokinetics of poly(\u03b5-caprolactone)-based micelles loaded with a photosensitizer","author":"Liu","year":"2020","journal-title":"J. Control Release"},{"key":"10.1016\/j.addr.2021.113829_b0345","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1208\/s12248-016-9969-z","article-title":"A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products","volume":"18","author":"Troiano","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2021.113829_b0350","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1023\/A:1011199028318","article-title":"Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer","volume":"12","author":"Harrington","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0355","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6603345","article-title":"Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer","volume":"95","author":"White","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2021.113829_b0360","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/annonc\/mdq234","article-title":"Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial","volume":"21","author":"Stathopoulos","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0365","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00280-011-1572-5","article-title":"Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer","volume":"68","author":"Stathopoulos","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0370","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/581363","article-title":"Lipoplatin formulation review article","volume":"2012","author":"Stathopoulos","year":"2012","journal-title":"J. Drug. Deliv."},{"key":"10.1016\/j.addr.2021.113829_b0375","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013169","article-title":"Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.addr.2021.113829_b0380","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00280-003-0719-4","article-title":"Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma","volume":"53","author":"William","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0385","first-page":"1065","article-title":"New liposomal formulations of cisplatin with improved therapeutic index","volume":"64","author":"Gerard","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0390","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejps.2017.03.003","article-title":"Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids","volume":"103","author":"Kieler-Ferguson","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0395","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijpharm.2014.09.009","article-title":"Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor","volume":"475","author":"Chen","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0400","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1517\/14656560802677874","article-title":"Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer","volume":"10","author":"Poon","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.addr.2021.113829_b0405","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1078-0432.CCR-16-2433","article-title":"Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions","volume":"24","author":"Tak","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2217\/nnm-2021-0019","article-title":"Sequentially stimuli-responsive anticancer nanomedicines","volume":"16","author":"Wei","year":"2021","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.addr.2021.113829_b0415","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nou265.21","article-title":"NT-23 * Phase 1\/2A study of glutathione pegylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases (BCBM) or recurrent high grade gliomas (HGG)","volume":"16","author":"Kerklaan","year":"2014","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0420","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0425","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: a next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.addr.2021.113829_b0430","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1200\/JCO.2019.37.15_suppl.3098","article-title":"A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors","volume":"37","author":"Johnson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0435","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2016.03.026","article-title":"A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system","volume":"229","author":"Song","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0440","doi-asserted-by":"crossref","first-page":"128ra139","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.113829_b0445","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","article-title":"Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors","volume":"22","author":"Hoff","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0450","first-page":"2019","article-title":"Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest\u00ae System for Detection of Circulating Tumor Cells","volume":"36","author":"\u010capoun","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0455","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial","volume":"4","author":"Autio","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0460","unstructured":"US-FDA, Doxorubicin hydrochloride liposome injection (Doxil\u00ae) approval letter (NDA 50-718\/S-50), 2015."},{"key":"10.1016\/j.addr.2021.113829_b0465","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(96)00453-X","article-title":"The design and development of DaunoXome(R) for solid tumor targeting in vivo","volume":"24","author":"Eric","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0470","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B","volume":"3","author":"Adler-moore","year":"1993","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2021.113829_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-9776(01)80001-1","article-title":"Liposome technology and the development of Myocet\u2122 (liposomal doxorubicin citrate)","volume":"10","author":"Swenson","year":"2001","journal-title":"Breast"},{"key":"10.1016\/j.addr.2021.113829_b0480","first-page":"13","article-title":"Drug release characteristics of lipid based benzoporphyrin derivative","volume":"6","author":"Chowdhary","year":"2003","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0485","first-page":"1165","article-title":"Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial","volume":"1","author":"Vail","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0490","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/0091270006288953","article-title":"Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients","volume":"46","author":"Bedikian","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0495","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12885-017-3377-3","volume":"17","author":"Burade","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2021.113829_b0500","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0505","unstructured":"US-FDA, DOXOrubicin Hydrochloride Liposome Injection approval letter (ANDA 208657), 2017."},{"key":"10.1016\/j.addr.2021.113829_b0510","unstructured":"US-FDA, Abraxane approval letter (NDA21-660), Clinical Pharmacology and Biopharmaceutics Review(s), 2005."},{"key":"10.1016\/j.addr.2021.113829_b0515","unstructured":"US-FDA, Ferumoxytol approval letter (NDA 22-180), Clinical Pharmacology and Biopharmaceutics Review(s), 2009."},{"key":"10.1016\/j.addr.2021.113829_b0520","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nbt0918-777","article-title":"Alnylam launches era of RNAi drugs","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2021.113829_b0525","unstructured":"US-FDA, Onpattro 2 mg\/mL injection for intravenous use approval letter (NDA 210922), 2018."},{"key":"10.1016\/j.addr.2021.113829_b0530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0609.1996.tb01348.x","article-title":"Amphotericin B Lipid Complex (Abelcet) in the treatment of invasive mycoses: the North American experience","volume":"57","author":"Lister","year":"1996","journal-title":"Eur. J. Haematol. Suppl."},{"key":"10.1016\/j.addr.2021.113829_b0535","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.smim.2017.09.007","article-title":"Modulating the immune system through nanotechnology","volume":"34","author":"Dacoba","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.addr.2021.113829_b0540","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.113829_b0545","doi-asserted-by":"crossref","first-page":"1900101","DOI":"10.1002\/advs.201900101","article-title":"Immunomodulatory Nanosystems","volume":"6","author":"Feng","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0550","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.113829_b0555","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1021\/acsnano.7b00978","article-title":"Efficient Nanovaccine Delivery in Cancer Immunotherapy","volume":"11","author":"Zhu","year":"2017","journal-title":"ACS nano"},{"key":"10.1016\/j.addr.2021.113829_b0560","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2147\/IJN.S125866","article-title":"Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens","volume":"12","author":"Gao","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2021.113829_b0565","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1016\/j.vaccine.2010.09.077","article-title":"Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation","volume":"28","author":"Hirosue","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.113829_b0570","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/smll.201300012","article-title":"Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice","volume":"9","author":"Mahony","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.addr.2021.113829_b0575","doi-asserted-by":"crossref","first-page":"1700426","DOI":"10.1002\/advs.201700426","article-title":"Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8(+) T Cell Responses","volume":"5","author":"Jiang","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0580","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/vaccines3030662","article-title":"Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy","volume":"3","author":"Fan","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.addr.2021.113829_b0585","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-14-0019-T","article-title":"Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes","volume":"2","author":"Jeanbart","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.addr.2021.113829_b0590","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.113829_b0595","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/anie.201508626","article-title":"Engineering Polymer Hydrogel Nanoparticles for Lymph Node-Targeted Delivery","volume":"55","author":"De Koker","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2021.113829_b0600","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2017.03.033","article-title":"Synthetic nanovaccines for immunotherapy","volume":"263","author":"Luo","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0605","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol"},{"key":"10.1016\/j.addr.2021.113829_b0610","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2021.113829_b0615","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrmicro.2017.60","article-title":"Viral effects on the content and function of extracellular vesicles","volume":"15","author":"Raab-Traub","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.addr.2021.113829_b0620","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.bcp.2011.12.037","article-title":"The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities","volume":"83","author":"Pant","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0625","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cellimm.2004.11.002","article-title":"Exosomes secreted from monocyte-derived dendritic cells support in vitro naive CD4+ T cell survival through NF-\u03baB activation","volume":"231","author":"Matsumoto","year":"2004","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.addr.2021.113829_b0630","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1073\/pnas.1131852100","article-title":"Direct stimulation of na\u00efve T cells by membrane vesicles from antigen-presenting cells: Distinct roles for CD54 and B7 molecules","volume":"100","author":"Hwang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2021.113829_b0635","first-page":"7","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.addr.2021.113829_b0640","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The Changing Landscape of Therapeutic Cancer Vaccines\u2014Novel Platforms and Neoantigen Identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0645","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-013-0029-2","article-title":"Multicomponent Meningococcal Serogroup B Vaccine (4CMenB; Bexsero\u00ae): A Review of its Use in Primary and Booster Vaccination","volume":"27","author":"Carter","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2021.113829_b0650","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.addr.2021.113829_b0655","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2007-03-079152","article-title":"Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo","volume":"110","author":"Bhatnagar","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.addr.2021.113829_b0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026588","article-title":"Exosomes from Plasmodium yoelii-Infected Reticulocytes Protect Mice from Lethal Infections","volume":"6","author":"Martin-Jaular","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.addr.2021.113829_b0665","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4049\/jimmunol.1103638","article-title":"Exosomes Isolated from Mycobacteria-Infected Mice or Cultured Macrophages Can Recruit and Activate Immune Cells In Vitro and In Vivo","volume":"189","author":"Singh","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2021.113829_b0670","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2021.03.016","article-title":"Extracellular vesicles as antigen carriers for novel vaccination avenues","volume":"173","author":"Mehanny","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0675","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2014.41","article-title":"MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease","volume":"28","author":"Kordelas","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.addr.2021.113829_b0680","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13287-018-0791-7","article-title":"Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine","volume":"9","author":"Keshtkar","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.addr.2021.113829_b0685","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13287-019-1398-3","article-title":"Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles","volume":"10","author":"Park","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.addr.2021.113829_b0690","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.addr.2020.12.006","article-title":"Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection","volume":"169","author":"Batty","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0695","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/biology10020094","article-title":"Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2","volume":"10","author":"Sabanovic","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.addr.2021.113829_b0700","doi-asserted-by":"crossref","unstructured":"S.-J. Tsai, C. Guo, N.A. Atai, S.J. Gould, Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination, bioRxiv, 2020, 2020.2011.2006.371419.","DOI":"10.1101\/2020.11.06.371419"},{"key":"10.1016\/j.addr.2021.113829_b0705","doi-asserted-by":"crossref","unstructured":"K. Polak, N. Greze, M. Lachat, D. Merle, S. Chiumento, C. Bertrand-Gaday, B. Trentin, R.Z. Mamoun, Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice, bioRxiv, 2020, 2020.2010.2028.357137.","DOI":"10.1101\/2020.10.28.357137"},{"key":"10.1016\/j.addr.2021.113829_b0710","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040307","article-title":"Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes","volume":"8","author":"Gurunathan","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.addr.2021.113829_b0715","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1248\/bpb.b18-00133","article-title":"Possibility of Exosome-Based Therapeutics and Challenges in Production of Exosomes Eligible for Therapeutic Application","volume":"41","author":"Yamashita","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2021.113829_b0720","article-title":"Boosting the Biogenesis and Secretion of Mesenchymal Stem Cell-Derived Exosomes","volume":"9","author":"Wang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.addr.2021.113829_b0725","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/wnan.1395","article-title":"Development and regulation of exosome-based therapy products","volume":"8","author":"Batrakova","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2021.113829_b0730","doi-asserted-by":"crossref","first-page":"31036","DOI":"10.3402\/jmahp.v4.31036","article-title":"Advanced therapy medicinal products: current and future perspectives","volume":"4","author":"Hanna","year":"2016","journal-title":"J. Mark. Access Health Policy"},{"key":"10.1016\/j.addr.2021.113829_b0735","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2019.07.005","article-title":"Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs","volume":"309","author":"Fulop","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0740","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.addr.2012.07.005","article-title":"A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines","volume":"64","author":"Szebeni","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0745","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","article-title":"Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome","volume":"8","author":"Szebeni","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2021.113829_b0750","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fchem.2018.00360","article-title":"Nanomedicine: Principles, Properties, and Regulatory Issues","volume":"6","author":"Soares","year":"2018","journal-title":"Front. Chem."},{"key":"10.1016\/j.addr.2021.113829_b0755","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijpharm.2015.06.024","article-title":"Nanocarriers for photodynamic therapy-rational formulation design and medium-scale manufacture","volume":"491","author":"Villa Nova","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0760","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijpharm.2016.05.029","article-title":"Novel polymeric micelles for drug delivery: Material characterization and formulation screening","volume":"509","author":"Janas","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0765","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11095-011-0555-x","article-title":"Comparative investigations on in vitro serum stability of polymeric micelle formulations","volume":"29","author":"Miller","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113829_b0770","doi-asserted-by":"crossref","first-page":"1596016","DOI":"10.1080\/20013078.2019.1596016","article-title":"Extracellular vesicle measurements with nanoparticle tracking analysis \u2013 An accuracy and repeatability comparison between NanoSight NS300 and ZetaView","volume":"8","author":"Bachurski","year":"2019","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.addr.2021.113829_b0775","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12032-020-1346-1","article-title":"Extracellular vesicle isolation from human renal cancer tissue","volume":"37","author":"Zieren","year":"2020","journal-title":"Med. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b0780","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-019-0509-6","article-title":"A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors","volume":"9","author":"Wang","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.addr.2021.113829_b0785","first-page":"375","article-title":"Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer","volume":"44","author":"Lopez-Berestein","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0790","first-page":"107","article-title":"Indium-111-labelled liposomes: dosimetry and tumour detection in patients with cancer","volume":"20","author":"Atsushi","year":"1993","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.addr.2021.113829_b0795","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/08982100701527981","article-title":"Conventional liposome performance and evaluation: lessons from the development of Vescan","volume":"17","author":"Jensen","year":"2007","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2021.113829_b0800","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.1991.476","article-title":"Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin","volume":"64","author":"Gabizon","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2021.113829_b0805","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b0810","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2019.05.012","article-title":"Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine","volume":"143","author":"Man","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113829_b0815","doi-asserted-by":"crossref","first-page":"22720","DOI":"10.1039\/C8NR07755J","article-title":"Dissociation of fluorescently labeled lipids from liposomes in biological environments challenges the interpretation of uptake studies","volume":"10","author":"M\u00fcnter","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2021.113829_b0820","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113829_b0825","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-018-3643-3","article-title":"Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil(\u00ae) or Caelyx(\u00ae) in advanced ovarian cancer","volume":"82","author":"Bhowmik","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0830","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00280-004-0825-y","article-title":"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study","volume":"54","author":"Mross","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b0835","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26040831","article-title":"Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin","volume":"26","author":"Kovshova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2021.113829_b0840","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0005-2736(94)90038-8","article-title":"Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes","volume":"1190","author":"Litzinger","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2021.113829_b0845","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1002\/anie.201003142","article-title":"A nanoparticle size series for in vivo fluorescence imaging","volume":"49","author":"Popovi\u0107","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2021.113829_b0850","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/nl900031y","article-title":"Mediating tumor targeting efficiency of nanoparticles through design","volume":"9","author":"Perrault","year":"2009","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2021.113829_b0855","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3762\/bjnano.5.151","article-title":"The protein corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles","volume":"5","author":"Docter","year":"2014","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.addr.2021.113829_b0860","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3762\/bjnano.10.101","article-title":"Serum type and concentration both affect the protein-corona composition of PLGA nanoparticles","volume":"10","author":"Partikel","year":"2019","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.addr.2021.113829_b0865","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2019.08.010","article-title":"A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes","volume":"143","author":"Wallenwein","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b0870","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpharm.2016.05.015","article-title":"Dealing with nanosafety around the globe-Regulation vs. innovation","volume":"509","author":"Wacker","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0875","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1038\/s41598-020-61624-9","article-title":"Routine, ensemble characterisation of electrophoretic mobility in high and saturated ionic dispersions","volume":"10","author":"Austin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.113829_b0880","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijpharm.2011.04.046","article-title":"A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation","volume":"414","author":"Wacker","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0885","first-page":"3087","article-title":"Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes","volume":"6","author":"Zhao","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2021.113829_b0890","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jbio.201300133","article-title":"Pharmacokinetic and biodistribution study following systemic administration of Fospeg\u00ae\u2013a Pegylated liposomal mTHPC formulation in a murine model","volume":"8","author":"Xie","year":"2015","journal-title":"J. Biophotonics"},{"key":"10.1016\/j.addr.2021.113829_b0895","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.nano.2015.02.021","article-title":"Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration","volume":"11","author":"van der Valk","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2021.113829_b0900","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.nano.2015.02.020","article-title":"Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy","volume":"11","author":"Lobatto","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2021.113829_b0905","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1039\/C4MT00340C","article-title":"Size- and surface chemistry-dependent pharmacokinetics and tumor accumulation of engineered gold nanoparticles after intravenous administration","volume":"7","author":"Wang","year":"2015","journal-title":"Metallomics"},{"key":"10.1016\/j.addr.2021.113829_b0910","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1021\/acs.molpharmaceut.7b00950","article-title":"Role of Extracellular Vesicle Surface Proteins in the Pharmacokinetics of Extracellular Vesicles","volume":"15","author":"Charoenviriyakul","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0915","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.3390\/ijms21124407","article-title":"Transport of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects of Inflammation","volume":"21","author":"Banks","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.113829_b0920","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1061186021000072447","article-title":"Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models","volume":"10","author":"Gabizon","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2021.113829_b0925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jconrel.2015.08.024","article-title":"Mechanistic model and analysis of doxorubicin release from liposomal formulations","volume":"217","author":"Fugit","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0930","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/10717540490265243","article-title":"The Effect of Different Lipid Components on the In Vitro Stability and Release Kinetics of Liposome Formulations","volume":"11","author":"Anderson","year":"2004","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2021.113829_b0935","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bbamem.2006.11.003","article-title":"Molecular studies of the gel to liquid-crystalline phase transition for fully hydrated DPPC and DPPE bilayers","volume":"1768","author":"Leekumjorn","year":"2007","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.addr.2021.113829_b0940","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acsomega.7b01235","article-title":"Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance","volume":"3","author":"Wei","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2021.113829_b0945","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0950","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-5793(92)80947-F","article-title":"Gelation of liposome interior. A novel method for drug encapsulation","volume":"312","author":"Lasic","year":"1992","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2021.113829_b0955","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2147\/IJN.S131786","article-title":"Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy","volume":"12","author":"Goh","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2021.113829_b0960","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1021\/acs.molpharmaceut.5b00065","article-title":"Finding the Needle in the Haystack: Characterization of Trace Crystallinity in a Commercial Formulation of Paclitaxel Protein-Bound Particles by Raman Spectroscopy Enabled by Second Harmonic Generation Microscopy","volume":"12","author":"Schmitt","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0965","first-page":"108","article-title":"Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs","volume":"2016","author":"Schilt","year":"1860","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2021.113829_b0970","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jconrel.2004.06.003","article-title":"Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery","volume":"98","author":"Shuai","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b0975","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ejpb.2016.04.011","article-title":"Insights into composition\/structure\/function relationships of Doxil\u00ae gained from \u201chigh-sensitivity\u201d differential scanning calorimetry","volume":"104","author":"Wei","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b0980","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10973-017-6394-1","article-title":"DSC for evaluating the encapsulation efficiency of lidocaine-loaded liposomes compared to the ultracentrifugation method","volume":"130","author":"Bakonyi","year":"2017","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.addr.2021.113829_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118733","article-title":"Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development","volume":"572","author":"Maksimenko","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0990","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijpharm.2018.11.014","article-title":"Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma","volume":"554","author":"Pereverzeva","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113829_b0995","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e13537","article-title":"A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors","volume":"35","author":"Filon","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.113829_b1000","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3762\/bjnano.10.244","article-title":"Frontiers in pharmaceutical nanotechnology","volume":"10","author":"Wacker","year":"2019","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.addr.2021.113829_b1005","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1208\/s12248-017-0126-0","article-title":"Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products","volume":"19","author":"Zou","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2021.113829_b1010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jpba.2013.08.005","article-title":"Structural characterization of iron oxide\/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD)","volume":"86","author":"Futterer","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2021.113829_b1015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.12693\/APhysPolA.127.534","article-title":"Micro-Raman Spectroscopy of Natural and Synthetic Ferritins and Their Mimetics","volume":"127","author":"Szybowicz","year":"2015","journal-title":"Acta Phys. Pol. A"},{"key":"10.1016\/j.addr.2021.113829_b1020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejps.2018.05.004","article-title":"How to measure release from nanosized carriers?","volume":"120","author":"Nothnagel","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113829_b1025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejps.2013.10.015","article-title":"Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs","volume":"57","author":"Bergstrom","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113829_b1030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.addr.2021.113829_b1035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4172\/2161-0444.1000368","article-title":"Development and Validation of a Method for Determination of Encapsulation Efficiency of CPT-11\/DSPE-mPEG2000 Nanoparticles","volume":"6","author":"Li","year":"2016","journal-title":"Med. Chem. (Los Angeles)"},{"key":"10.1016\/j.addr.2021.113829_b1040","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1002\/jcb.26617","article-title":"Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization","volume":"119","author":"Daneshmand","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.addr.2021.113829_b1045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2014.10.011","article-title":"Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method","volume":"197","author":"Fugit","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b1050","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1007\/s11095-015-1761-8","article-title":"Solid Phase Extraction as an Innovative Separation Method for Measuring Free and Entrapped Drug in Lipid Nanoparticles","volume":"32","author":"Guillot","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113829_b1055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/1871520617666171121124610","article-title":"Comparison of Physicochemical Properties of Generic Doxorubicin HCl Liposome Injection with the Reference Listed Drug","volume":"18","author":"Maiti","year":"2018","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.addr.2021.113829_b1060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2017.02.006","article-title":"The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers","volume":"115","author":"Janas","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b1065","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejpb.2018.03.010","article-title":"A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling","volume":"127","author":"Jung","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b1070","article-title":"Predicting the environmental emissions arising from conventional and nanotechnology-related pharmaceutical drug products","volume":"192","author":"Jung","year":"2020","journal-title":"Environ. Res."},{"key":"10.1016\/j.addr.2021.113829_b1075","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejpb.2018.11.012","article-title":"Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001","volume":"134","author":"Nothnagel","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461767","volume":"1635","author":"Caputo","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.addr.2021.113829_b1085","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s11095-015-1831-y","article-title":"Quantitative In Vitro Assessment of Liposome Stability and Drug Transfer Employing Asymmetrical Flow Field-Flow Fractionation (AF4)","volume":"33","author":"Holzschuh","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113829_b1090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13346-021-00918-5","article-title":"Asymmetric flow field-flow fractionation as a multifunctional technique for the characterization of polymeric nanocarriers","author":"Quattrini","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2021.113829_b1095","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/370308","article-title":"Modeling drug-carrier interaction in the drug release from nanocarriers","volume":"2011","author":"Zeng","year":"2011","journal-title":"J. Drug. Deliv."},{"key":"10.1016\/j.addr.2021.113829_b1100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-3659(02)00294-8","article-title":"Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems","volume":"84","author":"Shabbits","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b1105","article-title":"In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling","author":"Diaz de Leon-Ortega","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113829_b1110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijantimicag.2013.06.011","article-title":"Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration","volume":"42","author":"Malone","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.addr.2021.113829_b1115","first-page":"169","article-title":"In vitro - in vivo correlation: from theory to applications","volume":"9","author":"Emami","year":"2006","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113829_b1120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/s12248-019-0292-3","article-title":"PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective","volume":"21","author":"Stillhart","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2021.113829_b1125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13318-017-0430-1","article-title":"Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals","volume":"43","author":"Reijers","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.addr.2021.113829_b1130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1208\/s12248-016-0010-3","article-title":"Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles","volume":"19","author":"Li","year":"2017","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.addr.2021.113829_b1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometr. Syst. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b1140","unstructured":"US-FDA, Draft Guidance for Industry: The Use of Physiologically Based Pharmacokinetic Analyses \u2014 Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls, 2020."},{"key":"10.1016\/j.addr.2021.113829_b1145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-019-0298-x","article-title":"Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report","volume":"21","author":"Heimbach","year":"2019","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2021.113829_b1150","unstructured":"EMA, Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation, 2018."},{"key":"10.1016\/j.addr.2021.113829_b1155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2011.00031","article-title":"A Workflow for Global Sensitivity Analysis of PBPK Models","volume":"2","author":"McNally","year":"2011","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b1160","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1158\/1078-0432.CCR-05-1365","article-title":"Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model","volume":"11","author":"Arnold","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2021.113829_b1165","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2021.113829_b1170","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2021.113829_b1175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2021.113829_b1180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.addr.2021.113829_b1185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1016243313027","article-title":"Comparative Tissue Distribution and Elimination of Amphotericin B Colloidal Dispersion (Amphocil\u00ae) and Fungizone\u00ae After Repeated Dosing in Rats","volume":"12","author":"Wang","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113829_b1190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/AAC.36.2.299","article-title":"Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs","volume":"36","author":"Fielding","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113829_b1195","doi-asserted-by":"crossref","first-page":"28","DOI":"10.14227\/DT260319P28","article-title":"In Vitro Performance Testing of Nanoparticulate Drug Products for Parenteral Administration","volume":"26","author":"Fecioru","year":"2019","journal-title":"Dissolut. Technol."},{"key":"10.1016\/j.addr.2021.113829_b1200","doi-asserted-by":"crossref","unstructured":"Wacker M.G., Lu X., Burke M., Nir I., Fahmy R., Zaidi K., Testing the In-Vitro Product Performance of Nanomaterial-Based Drug Products: View of the USP Expert Panel, Pharmacop. Forum 47(6), (Accepted for public consultation).","DOI":"10.14227\/DT290122P6"},{"key":"10.1016\/j.addr.2021.113829_b1205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2011.05.022","article-title":"APN\/CD13-targeting as a strategy to alter the tumor accumulation of liposomes","volume":"154","author":"Dunne","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113829_b1210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.addr.2021.113829_b1215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/wics.1310","article-title":"Bioavailability and Bioequivalence in Drug Development","volume":"6","author":"Chow","year":"2014","journal-title":"Wiley Interdiscip. Rev. Comput. Stat."},{"key":"10.1016\/j.addr.2021.113829_b1220","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J. Pharm. Sci."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21002210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21002210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:20:34Z","timestamp":1759209634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21002210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":244,"alternative-id":["S0169409X21002210"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.113829","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanomedicine at the crossroads \u2013 A quick guide for IVIVC","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.113829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113829"}}